MLYS - NASDAQ

Mineralys Therapeutics, Inc.

MLYS·NASDAQ

$25.06

-19%

HealthcareBiotechnology

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.66B

EPS-2.2900

P/E Ratio-10.94

Earnings Date08/11/2026

mlys

Total Other Income Expenses Net

Last Annual Value

15.95M

3-Year CAGR

112%

5-Year CAGR

104%

10-Year CAGR

43%

Adjust for Inflation

Mineralys Therapeutics, Inc. Competitors Analysis of Total Other Income Expenses Net

MLYS · NASDAQ

Company	Total Other Income Expenses Net	CAGR 3Y	CAGR 5Y	CAGR 10Y
Mineralys Therapeutics, Inc. NASDAQ:MLYS	15.95M	7.7%	N/A	N/A
Cidara Therapeutics, Inc. NASDAQ:CDTX	5.81M	42.8%	N/A	35.9%
Catalyst Pharmaceuticals, Inc. NASDAQ:CPRX	25.74M	49.5%	146.6%	35.8%
Scholar Rock Holding Corporation NASDAQ:SRRK	6.71M	6.8%	N/A	116.2%
IDEAYA Biosciences, Inc. NASDAQ:IDYA	45.62M	28.6%	146.0%	N/A
Agios Pharmaceuticals, Inc. NASDAQ:AGIO	58.34M	14.0%	21.6%	36.9%
Apellis Pharmaceuticals, Inc. NASDAQ:APLS	-31.32M	N/A	N/A	N/A
Adaptive Biotechnologies Corporation NASDAQ:ADPT	-2.33M	N/A	N/A	N/A
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX	3.24M	-43.5%	N/A	N/A
Beam Therapeutics Inc. NASDAQ:BEAM	303.70M	88.5%	69.3%	N/A

Mineralys Therapeutics, Inc. Fair Value Envelope

MLYS · NASDAQ

Our analysis suggests that MLYS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $25.06, this represents a potential HIDDEN relative to our calculated worth for Mineralys Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $25.06

Related Guides

Blog Categories

Continue your MLYS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.